CompletedPhase 1NCT06480968

CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Connecta Therapeutics, S.L.
Principal Investigator
Rafael De la Torre, Pharm, PhD
Hospital del Mar Medical Research Institute (IMIM)
Intervention
CTH120(drug)
Enrollment
76 enrolled
Eligibility
18-55 years · All sexes
Timeline
2023 – 2024

Study locations (1)

Collaborators

Hospital del Mar Research Institute (IMIM) · Adknoma Health Research · Ministry of Science and Innovation, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06480968 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome →

← Back to all trials